Abstract Body

ART-PRO pilot trial showed that at 48 weeks DTG+3TC was effective in maintaining virologic control despite history of lamivudine resistance and persistence of archived 3TC mutations detected by NGS. Here we present resistance analysis and virologic outcomes after 80 weeks of DTG+3TC treatment.

Open, single-arm, pilot trial including HIV-1 infected adults, INSTI-naïve, CD4 count >350 cell/μL, VL< 50 copies/mL for 1 year prior to study entry. Participants were excluded if baseline proviral DNA population genotyping detected M184V/I or K65R/E/N. Baseline proviral DNA NGS genotype was retrospectively performed to detect resistance minority variants. All participants were switched to DTG+3TC.

41 participants (78% male) switched to DTG+3TC: 21 participants had M184V/I or K65R/E/N in historical plasma genotyping and 20 had not. At baseline: median CD4 661, ART duration 18 years, duration of suppressed plasma HIV RNA 7.7 years, number of prior ART regimens 6. Participants with historical 3TC resistance were significantly less likely to receive a regimen including 3TC before the switch (p<0.001). NGS of baseline proviral DNA detected M184V/I at >5%/>20% thresholds in 67%/29% of participants with and 15%/5% of participants without history of 3TC resistance. K65R was detected in proviral DNA by NGS only in participants with historical resistance to 3TC (9.5%/5% at the >5%/>20% cut-off respectively).

At week 80, 87.8% of participants (37/41) remained with VL< 50 copies/mL (Table 1). There were no virologic failures through week 80. Of the 21 participants with historical 3TC resistance, 3 prematurely discontinued with suppressed viremia (2 protocol violations, one AE [insomnia, W8]). One participant without historical 3TC resistance declined to participate in the 144w study extension.  There were 12 blips, 6 in the group with historical resistance. There were 30 related AE, 4/30 were severe and only 1 led to discontinuation.

In this pilot trial, DTG+3TC was effective maintaining long-term virologic control after 80 weeks of follow up despite history of 3TC resistance and presence of archived 3TC mutations detected by NGS. 144-week study extension of our trial is ongoing